GLP-1 Prescriptions After the 503B Ban: What Changes and What Doesn't

The FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List affects the pharmacy supply chain behind your prescription — not the prescription itself. Your doctor can still prescribe GLP-1 medications.

What You Need to Know

What changes: the source of compounded medication shifts from large-scale 503B outsourcing facilities to patient-specific 503A compounding pharmacies (smaller scale, potentially higher cost) or brand-name medications through manufacturer savings programs. What doesn't change: your eligibility, your prescription validity, 503A compounding legality, brand-name availability, or oral Wegovy access. If you're currently on compounded GLP-1 medication, confirm whether your provider uses 503A or 503B pharmacies. If 503B, ask about their transition plan before the expected Q3 2026 final rule..

The Details

Recommended Providers